Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

Restorative Gel Could Help Reverse Paralysis

By BiotechDaily International staff writers
Posted on 28 May 2013
A biodegradable implant that delivers a therapeutic gel could help restore healthy nerve function in degenerative disorders such as Parkinson's disease.

Researchers at Tel Aviv University (Israel) developed the implant, which is a soft, biodegradable tube that serves as a physical bridge to help the nerve ends connect. Lining the inside of the biodegradable tube is a guiding regeneration gel (GRG), a transparent, highly viscous, malleable, and adaptable gel that increases nerve growth and healing, helping the severed nerve ends to rejoin. But the GRG not only aids reconnection and cell preservation, it can also support their survival while being used for therapy and transplantation.

The key to the regeneration process lies in the composition of the gel, with three main components: superoxide dismutase (SOD) antioxidants, which exhibit high anti-inflammatory activities; synthetic laminin-derived peptides, which act as a railway or track for the nerve fibers to grow along; and hyaluronic acid, commonly found in the human fetus, which serves as a buffer against drying, a major danger for most implants. These components allow the nerve to heal the way a fetus does in the womb - quickly and smoothly.

Research to-date has shown that GRG stimulates cell growth, neuronal sprouting, and extracellular matrix (ECM) formation, supporting cells in vitro and in vivo upon implantation. It also supports three dimensional (3D) growth and differentiation of various cell types (embryonic, adult stem cells, and preneuronal cells). The implications for therapeutic applications include peripheral nerves reconstruction, cell therapy, corneal preservation, wound healing, and as a postirradiation tissue cavity filler.

“The implant has already been tested in animal models, and the gel by itself can be used as a stand-alone product, acting as an aid to cell therapy,” said GRG codeveloper Shimon Rochkind, MD. “When grown in the gel, cells show excellent development, as well as intensive fiber growth. This could have implications for the treatment of diseases such as Parkinson's.”

Related Links:

Tel Aviv University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.